(ANGO) AngioDynamics - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 405m USD | Total Return: 4.6% in 12m

Medical Devices, Vascular Treatment, Oncology Tools, Surgical Instruments
Total Rating 38
Safety 32
Buy Signal 0.13
Medical Instruments & Supplies
Industry Rotation: +4.2
Market Cap: 405M
Avg Turnover: 4.62M USD
ATR: 5.48%
Peers RS (IBD): 55.2
Risk 5d forecast
Volatility58.0%
Rel. Tail Risk-18.7%
Reward TTM
Sharpe Ratio0.36
Alpha-5.31
Character TTM
Beta0.373
Beta Downside2.609
Drawdowns 3y
Max DD52.78%
CAGR/Max DD0.08
EPS (Earnings per Share) EPS (Earnings per Share) of ANGO over the last years for every Quarter: "2021-02": 0.02, "2021-05": -0.5053, "2021-08": -0.02, "2021-11": -0.02, "2022-02": 0.03, "2022-05": 0.01, "2022-08": -0.06, "2022-11": 0.01, "2023-02": -0.03, "2023-05": 0.02, "2023-08": -0.12, "2023-11": -0.05, "2024-02": -0.16, "2024-05": -0.06, "2024-08": -0.11, "2024-11": -0.04, "2025-02": 0.03, "2025-05": -0.03, "2025-08": -0.1, "2025-11": -0.1529, "2026-02": 0.02,
EPS CAGR: 20.30%
EPS Trend: -21.1%
Last SUE: 1.57
Qual. Beats: 1
Revenue Revenue of ANGO over the last years for every Quarter: 2021-02: 71.182, 2021-05: 76.842, 2021-08: 76.971, 2021-11: 78.28, 2022-02: 73.97, 2022-05: 86.998, 2022-08: 81.537, 2022-11: 85.429, 2023-02: 80.712, 2023-05: 91.074, 2023-08: 78.679, 2023-11: 79.073, 2024-02: 75.182, 2024-05: 70.98, 2024-08: 67.491, 2024-11: 72.845, 2025-02: 72.004, 2025-05: 80.158, 2025-08: 75.711, 2025-11: 79.433, 2026-02: 78.423,
Rev. CAGR: -2.73%
Rev. Trend: -52.1%
Last SUE: 0.43
Qual. Beats: 0

Warnings

High Debt/EBITDA (8.7) with thin interest coverage (-139.9)

Interest Coverage Ratio -139.9 is critical

Altman Z'' -9.53 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: ANGO AngioDynamics

AngioDynamics, Inc. (ANGO) is a medical technology company. It develops, manufactures, and sells medical, surgical, and diagnostic devices.

The companys product portfolio addresses peripheral vascular disease, oncology, and surgical applications. Key products include the Auryon Atherectomy system for lesion removal and the AlphaVac mechanical thrombectomy system for blood clot management. The medical device sector is characterized by innovation and regulatory oversight.

AngioDynamics also offers the NanoKnife IRE Ablation System for soft tissue ablation and various peripheral products like angiographic catheters and guidewires. Their business model focuses on providing specialized tools for minimally invasive procedures.

Further research on platforms like ValueRay can provide deeper insights into ANGOs financial performance and market position.

Headlines to Watch Out For
  • Auryon Atherectomy system sales drive revenue growth
  • AlphaVac thrombectomy system adoption boosts market share
  • NanoKnife IRE Ablation System expands oncology treatment options
  • Regulatory approvals impact new product launches
  • Healthcare spending trends influence device demand
Piotroski VR‑10 (Strict) 3.5
Net Income: -31.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 10.45 > 1.0
NWC/Revenue: 28.52% < 20% (prev 33.28%; Δ -4.76% < -1%)
CFO/TA 0.02 > 3% & CFO 4.45m > Net Income -31.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.35 > 1.5 & < 3
Outstanding Shares: last quarter (41.6m) vs 12m ago 1.82% < -2%
Gross Margin: 53.45% > 18% (prev 0.54%; Δ 5.29k% > 0.5%)
Asset Turnover: 114.9% > 50% (prev 99.27%; Δ 15.63% > 0%)
Interest Coverage Ratio: -139.9 > 6 (EBITDA TTM -3.89m / Interest Expense TTM 194k)
Altman Z'' -9.53
A: 0.34 (Total Current Assets 155.6m - Total Current Liabilities 66.1m) / Total Assets 260.7m
B: -1.74 (Retained Earnings -454.5m / Total Assets 260.7m)
C: -0.10 (EBIT TTM -27.1m / Avg Total Assets 273.0m)
D: -5.17 (Book Value of Equity -451.4m / Total Liabilities 87.3m)
Altman-Z'' Score: -9.53 = D
Beneish M -3.19
DSRI: 0.84 (Receivables 45.6m/49.0m, Revenue 313.7m/283.3m)
GMI: 1.02 (GM 53.45% / 54.36%)
AQI: 1.03 (AQ_t 0.29 / AQ_t-1 0.28)
SGI: 1.11 (Revenue 313.7m / 283.3m)
TATA: -0.14 (NI -31.4m - CFO 4.45m) / TA 260.7m)
Beneish M-Score: -3.19 (Cap -4..+1) = AA
What is the price of ANGO shares? As of April 14, 2026, the stock is trading at USD 10.24 with a total of 327,893 shares traded.
Over the past week, the price has changed by +4.07%, over one month by -3.40%, over three months by +1.69% and over the past year by +4.60%.
Is ANGO a buy, sell or hold? AngioDynamics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ANGO.
  • StrongBuy: 2
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ANGO price?
Analysts Target Price 18 75.8%
AngioDynamics (ANGO) - Fundamental Data Overview as of 13 April 2026
P/E Forward = 96.1538
P/S = 1.2907
P/B = 2.3358
P/EG = 1.4079
Revenue TTM = 313.7m USD
EBIT TTM = -27.1m USD
EBITDA TTM = -3.89m USD
 Long Term Debt = unknown (none)
 Short Term Debt = 1.84m USD (from shortTermDebt, last fiscal year)
Debt = 3.95m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -33.9m USD (recalculated: Debt 3.95m - CCE 37.8m)
Enterprise Value = 371.1m USD (404.9m + Debt 3.95m - CCE 37.8m)
Interest Coverage Ratio = -139.9 (Ebit TTM -27.1m / Interest Expense TTM 194k)
EV/FCF = 246.9x (Enterprise Value 371.1m / FCF TTM 1.50m)
FCF Yield = 0.41% (FCF TTM 1.50m / Enterprise Value 371.1m)
FCF Margin = 0.48% (FCF TTM 1.50m / Revenue TTM 313.7m)
Net Margin = -10.00% (Net Income TTM -31.4m / Revenue TTM 313.7m)
Gross Margin = 53.45% ((Revenue TTM 313.7m - Cost of Revenue TTM 146.0m) / Revenue TTM)
Gross Margin QoQ = 52.89% (prev 53.05%)
Tobins Q-Ratio = 1.42 (Enterprise Value 371.1m / Total Assets 260.7m)
Interest Expense / Debt = 2.23% (Interest Expense 88.0k / Debt 3.95m)
Taxrate = 21.0% (US default 21%)
NOPAT = -21.4m (EBIT -27.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.35 (Total Current Assets 155.6m / Total Current Liabilities 66.1m)
Debt / Equity = 0.02 (Debt 3.95m / totalStockholderEquity, last quarter 173.4m)
 Debt / EBITDA = 8.71 (negative EBITDA) (Net Debt -33.9m / EBITDA -3.89m)
 Debt / FCF = -22.53 (Net Debt -33.9m / FCF TTM 1.50m)
Total Stockholder Equity = 177.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.50% (Net Income -31.4m / Total Assets 260.7m)
RoE = -17.65% (Net Income TTM -31.4m / Total Stockholder Equity 177.9m)
RoCE = -13.95% (EBIT -27.1m / Capital Employed (Total Assets 260.7m - Current Liab 66.1m))
 RoIC = -12.06% (negative operating profit) (NOPAT -21.4m / Invested Capital 177.9m)
 WACC = 7.24% (E(404.9m)/V(408.9m) * Re(7.29%) + D(3.95m)/V(408.9m) * Rd(2.23%) * (1-Tc(0.21)))
Discount Rate = 7.29% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 0.82%
[DCF] Terminal Value 74.35% ; FCFF base≈1.50m ; Y1≈987k ; Y5≈451k
[DCF] Fair Price = 1.07 (EV 10.4m - Net Debt -33.9m = Equity 44.3m / Shares 41.3m; r=7.24% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -21.09 | EPS CAGR: 20.30% | SUE: 1.57 | # QB: 1
Revenue Correlation: -52.11 | Revenue CAGR: -2.73% | SUE: 0.43 | # QB: 0
EPS next Quarter (2026-08-31): EPS=-0.10 | Chg7d=-0.042 | Chg30d=-0.042 | Revisions Net=-1 | Analysts=3
EPS next Year (2027-05-31): EPS=-0.22 | Chg7d=-0.110 | Chg30d=-0.110 | Revisions Net=-1 | Growth EPS=-8.2% | Growth Revenue=+5.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle